Athenex (ATNX) Stock Price Up 6.3% After Insider Buying Activity

Shares of Athenex Inc (NASDAQ:ATNX) rose 6.3% during trading on Monday following insider buying activity. The stock traded as high as $15.32 and last traded at $15.01. Approximately 551,113 shares traded hands during trading, an increase of 46% from the average daily volume of 378,528 shares. The stock had previously closed at $14.12.

Specifically, Director Jinn Wu acquired 10,000 shares of the business’s stock in a transaction on Friday, February 9th. The shares were acquired at an average price of $13.64 per share, with a total value of $136,400.00. Following the completion of the transaction, the director now owns 249,208 shares in the company, valued at $3,399,197.12. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Johnson Yiu Nam Lau acquired 20,000 shares of the business’s stock in a transaction on Thursday, February 8th. The stock was acquired at an average cost of $14.40 per share, for a total transaction of $288,000.00. Following the transaction, the chief executive officer now owns 2,767,922 shares of the company’s stock, valued at approximately $39,858,076.80. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 60,000 shares of company stock worth $853,700.

Several research analysts have weighed in on ATNX shares. Deutsche Bank set a $20.00 price objective on Athenex and gave the stock a “buy” rating in a research report on Wednesday, January 17th. JPMorgan Chase & Co. boosted their price objective on Athenex from $22.20 to $23.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 24th. Finally, BidaskClub raised Athenex from a “sell” rating to a “hold” rating in a research report on Thursday, January 18th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $27.80.

The company has a market cap of $944.28 and a P/E ratio of -5.44.

Athenex (NASDAQ:ATNX) last issued its earnings results on Thursday, November 9th. The company reported ($0.30) earnings per share (EPS) for the quarter. research analysts anticipate that Athenex Inc will post -2.3 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of ATNX. Bank of New York Mellon Corp bought a new stake in shares of Athenex in the second quarter valued at $240,000. Vanguard Group Inc. bought a new stake in shares of Athenex in the second quarter valued at $800,000. California Public Employees Retirement System bought a new stake in shares of Athenex in the second quarter valued at $800,000. OxFORD Asset Management LLP bought a new stake in shares of Athenex in the second quarter valued at $956,000. Finally, Tudor Investment Corp ET AL bought a new stake in shares of Athenex in the second quarter valued at $320,000. Hedge funds and other institutional investors own 2.65% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Athenex (ATNX) Stock Price Up 6.3% After Insider Buying Activity” was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.thelincolnianonline.com/2018/02/12/athenex-atnx-stock-price-up-6-3-after-insider-buying-activity.html.

About Athenex

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply